Introduction: Favorable outcomes are observed after treatment with standard chemoradiotherapy (CRT) for Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) patients. The consistent growing interest on treatment-related toxicity burden, potentially jeopardizing survivors’ quality of life, led clinicians to investigate possible de-escalation strategies. Materials and Methods: A comprehensive systematic literature search of clinical trials was performed through the EMBASE database to provide an overview of the de-escalation strategies spectrum. Additionally, hand searching and clinicaltrials.gov were also used. Results: Herein, we report and discuss different approaches to de-escalation of therapy, with respect to both local and systemic strategies. Conclusions: Several promising de-escalation experiences have been published. However, while further evidence is awaited, no changes in the management nor deviation from the standard of care should be made outside of clinical trials.

Decreasing treatment burden in HPV-related OPSCC: A systematic review of clinical trials

Franco P.
Ultimo
Conceptualization
2021-01-01

Abstract

Introduction: Favorable outcomes are observed after treatment with standard chemoradiotherapy (CRT) for Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) patients. The consistent growing interest on treatment-related toxicity burden, potentially jeopardizing survivors’ quality of life, led clinicians to investigate possible de-escalation strategies. Materials and Methods: A comprehensive systematic literature search of clinical trials was performed through the EMBASE database to provide an overview of the de-escalation strategies spectrum. Additionally, hand searching and clinicaltrials.gov were also used. Results: Herein, we report and discuss different approaches to de-escalation of therapy, with respect to both local and systemic strategies. Conclusions: Several promising de-escalation experiences have been published. However, while further evidence is awaited, no changes in the management nor deviation from the standard of care should be made outside of clinical trials.
File in questo prodotto:
File Dimensione Formato  
clean manuscript CROH REV.pdf

file disponibile solo agli amministratori

Tipologia: Documento in Pre-print
Licenza: Creative commons
Dimensione 449.29 kB
Formato Adobe PDF
449.29 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11579/136640
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
social impact